FDA Inspection
Novo Nordisk Inc.Novo Nordisk Inc. – FDA Inspection, Apr 13, 2017
Record Details
This FDA Inspection record concerns Novo Nordisk Inc., with an inspection on April 13, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 1d5c8257-f349-440a-9ebf-72db3b05a4f4
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1013344
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 312.50General responsibilities of sponsors
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Novo Nordisk Inc.
10| Date | Classification | Office | Project area |
|---|---|---|---|
| February 7, 2025 | OAI | Bioresearch Monitoring | |
| December 21, 2022 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| June 8, 2017 | Not classified | New Jersey District Office | |
| July 22, 2016 | NAI | Center for Devices and Radiological Health | Postmarket Assurance: Devices |
| April 12, 2016 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for Novo Nordisk Inc.
- FDA Inspection 1255957 - 2025-02-07
- FDA Inspection 1194065 - 2022-12-21
- FDA Inspection 1018484 - 2017-06-08
- FDA Inspection 983531 - 2016-07-22
- FDA Inspection 968597 - 2016-04-12
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.